Abstract:BACKGROUND Gastric cancer (GC) is a highly aggressive malignancy with a heterogeneous nature, which makes prognosis prediction and treatment determination difficult. Inflammation is now recognized as one of the hallmarks of cancer and plays an important role in the aetiology and continued growth of tumours. Inflammation also affects the prognosis of GC patients. Recent reports suggest that a number of inflammatory-related biomarkers are useful for predicting tumour prognosis. However, the importance of inflammatory-related biomarkers in predicting the prognosis of GC patients is still unclear. AIM To investigate inflammatory-related biomarkers in predicting the prognosis of GC patients. METHODS In this study, the mRNA expression profiles and corresponding clinical information of GC patients were obtained from the Gene Expression Omnibus (GEO) database (GSE66229). An inflammatory-related gene prognostic signature model was constructed using the least absolute shrinkage and selection operator Cox regression model based on the GEO database. GC patients from the GSE26253 cohort were used for validation. Univariate and multivariate Cox analyses were used to determine the independent prognostic factors, and a prognostic nomogram was established. The calibration curve and the area under the curve based on receiver operating characteristic analysis were utilized to evaluate the predictive value of the nomogram. The decision curve analysis results were plotted to quantify and assess the clinical value of the nomogram. Gene set enrichment analysis was performed to explore the potential regulatory pathways involved. The relationship between tumour immune infiltration status and risk score was analysed via Tumour Immune Estimation Resource and CIBERSORT. Finally, we analysed the association between risk score and patient sensitivity to commonly used chemotherapy and targeted therapy agents. RESULTS A prognostic model consisting of three inflammatory-related genes (MRPS17, GUF1, and PDK4) was constructed. Independent prognostic analysis revealed that the risk score was a separate prognostic factor in GC patients. According to the risk score, GC patients were stratified into high- and low-risk groups, and patients in the high-risk group had significantly worse prognoses according to age, sex, TNM stage and Lauren type. Consensus clustering identified three subtypes of inflammation that could predict GC prognosis more accurately than traditional grading and staging. Finally, the study revealed that patients in the low-risk group were more sensitive to certain drugs than were those in the high-risk group, indicating a link between inflammation-related genes and drug sensitivity. CONCLUSION In conclusion, we established a novel three-gene prognostic signature that may be useful for predicting the prognosis and personalizing treatment decisions of GC patients.

Identification of Prognostic Biomarkers for Gastric Cancer by Gene Expression Analysis

Identification of Prognostic Biomarkers in Gastric Cancer Using Endoscopic Biopsy Samples

Identification of Significant Biomarkers and Pathways Associated with Gastric Carcinogenesis by Whole Genome-Wide Expression Profiling Analysis

Discovery and Validation of Prognostic Markers in Gastric Cancer by Genome-Wide Expression Profiling

Gene Expression Profile Predicts Patient Survival of Gastric Cancer After Surgical Resection

Discovery of Prognostic Signature Genes for Overall Survival Prediction in Gastric Cancer

Prognostic Value of a 25-Gene Assay in Patients with Gastric Cancer after Curative Resection

Identification of Potential Biomarkers Associated with Prognosis in Gastric Cancer via Bioinformatics Analysis

Proteomic and Metabolic Signaling Pathways in Different Prognosis of Gastric Cancer.

Identifying Novel Cell Glycolysis-Related Gene Signature Predictive of Overall Survival in Gastric Cancer

Identification of Differentially Expressed Genes in Gastric Cancer by High Density Cdna Microarray.

Prognostic Implications Of Novel Gene Signatures In Gastric Cancer Microenvironment

Identification of Key Genes and Signaling Pathways Associated with the Progression of Gastric Cancer

Bioinformatics Evaluation of a Novel Angiogenesis Related Genes-Based Signature for Predicting Prognosis and Therapeutic Efficacy in Patients with Gastric Cancer.

Identification and Validation of an Individualized Autophagy-Clinical Prognostic Index in Gastric Cancer Patients

Identification of An Immune Signature Predicting Prognosis Risk of Patients in Gastric Cancer

Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy

Bioinformatics Analysis and Identification of Potential Biomarkers in Gastric Cancer

Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer

Protein Expression Profiles and Clinicopathologic Characteristics Associate with Gastric Cancer Survival

Identification of a novel inflammatory-related gene signature to evaluate the prognosis of gastric cancer patients